NCT06168929已完成1 期
Bioequivalence Study of 2 Sizes of SHR4640 Tablets in Healthy Subjects (Randomized, Open, Single Dose, Two Sequences, Two Cycles, Self-Crossover Control)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 1
- 主要终点
- PK parameters of SHR4640: AUC0-t
研究概览
简要总结
The study is being conducted to evaluate the pharmacokinetic, and safety of two sizes of SHR4640 tablets in healthy adults, to explore the bioequivalence between two sizes of SHR4640 tablets.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Able and willing to provide a written informed consent.
- •18 years to 45 years (inclusive).
- •Body weight should above 45 kg, and body mass index should be between 19 and 28 kg/m2 (inclusive).
- •The physical examination, vital signs, laboratory examination and electrocardiogram are not abnormal or abnormal but with no clinical significance.
排除标准
- •Pregnant or nursing women.
- •No birth control 1 weeks before screening or until one week after SHR4640 administration.
- •Average daily alcohol consume more than 14g for female or more than 28g for male within 1 month before screening, or baseline alcohol screening is positive.
- •Smokers (average daily smoking of 5 cigarettes or more in the 3 months before screening).
- •Subject with a history of substance abuse and drug abuse.
- •The investigators determined that other conditions were inappropriate for participation in this clinical trial.
- •sUA level ≥480 μmol/L.
- •eGFR < 90 mL/min/1.73 m
- •Positive result for human immunodeficiency virus (HIV), hepatitis C virus antibody, or syphilis antibody, or hepatitis B surface antigen.
- •12-lead electrocardiogram (ECG) showed abnormal and clinically significant.
- •Cardiovascular, neuropsychiatric, respiratory, digestive tract, endocrine and other systemic diseases within 1 year before screening, which were judged to be serious by the investigators.
- •History of hypersensitivity to SHR4640 or its analogues.
- •History or suspected crystals or stones in the urinary system during the screening period of B-ultrasound.
- •History of been diagnosed with acute kidney injury in the past or screening period.
- •Had undergone major surgery within 3 months prior to screening, or have not recovered from surgery, or plan major surgery during the study.
- •Blood donation within 1 month before screening; Or patients with trauma or major surgical procedures who donated blood or lost blood > 400 mL in the 3 months prior to screening.
- •Has unsuitable venous for blood sampling.
- •Received the last dose of a study drug (or treatment with a medical device) within 3 months or 5 T1/2 (whichever is longer) of the screening or are currently participating in another study of a study drug (or medical device).
- •Have received or been exposed to other live vaccines or live attenuated vaccines within 3 months prior to Day 1, or who plan to receive live vaccines or live attenuated vaccines during the study.
- •Consumes grapefruit and/or poppy seed within 48 hours before SHR4640 administration.
- •Taken any prescription drugs, over-the-counter drugs, herbal medicines or food supplements within 2 weeks before screening.
研究组 & 干预措施
Treatment group B
Experimental
干预措施: SHR4640 (Drug)
Treatment group A
Experimental
干预措施: SHR4640 (Drug)
结局指标
主要结局
PK parameters of SHR4640: AUC0-t
时间窗: 0 hour to 72 hour after administration
PK parameters of SHR4640: AUC0-inf
时间窗: 0 hour to 72 hour after administration
PK parameters of SHR4640: Cmax
时间窗: 0 hour to 72 hour after administration
次要结局
- PK parameters of SHR4640: CL/F(0 hour to 72 hour after administration)
- PK parameters of SHR4640: t1/2(0 hour to 72 hour after administration)
- PK parameters of SHR4640: Tmax(0 hour to 72 hour after administration)
- PK parameters of SHR4640: Vz/F(0 hour to 72 hour after administration)
- Adverse events(from ICF signing date to approximate day 13)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With GoutGoutNCT03131583Jiangsu HengRui Medicine Co., Ltd.15
已完成
1 期
Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy SubjectsHyperuricemiaNCT05954169Jiangsu HengRui Medicine Co., Ltd.16
已完成
1 期
PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT IntervalGout and HyperuricemiaNCT06196580Jiangsu HengRui Medicine Co., Ltd.24
已完成
1 期
Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control)Healthy Male SubjectsNCT04850638Jiangsu HengRui Medicine Co., Ltd.18
已完成
1 期
A SHR0302 BA Study on Healthy SubjectsAutoimmune DiseasesNCT06202612Jiangsu HengRui Medicine Co., Ltd.16